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Abstract Human cytomegalovirus (HCMV) encodes
numerous proteins and microRNAs that function to
evade the immune response and allow the virus to
replicate and disseminate in the face of a competent
innate and acquired immune system. The establishment
of a latent infection by CMV, which if completely
quiescent at the level of viral gene expression would
represent an ultimate in immune evasion strategies, is
not sufficient for lifelong persistence and dissemination
of the virus. CMV needs to reactivate and replicate in a
lytic cycle of infection in order to disseminate further,
which occurs in the face of a fully primed secondary
immune response. Without reactivation, latency itself
would be redundant for the virus. It is also becoming
clear that latency is not a totally quiescent state, but is
characterized by limited viral gene expression. There-
fore, the virus also needs immune evasion strategies
during latency. An effective immune response to CMV
is required or viral replication will cause morbidity and
ultimately mortality in the host. There is clearly a com-
plex balance between virus immune evasion and host
immune recognition over a lifetime. This poses the
important question of whether long-term evasion or
manipulation of the immune response driven by CMV
is detrimental to health. In this meeting report, three
groups used the murine model of CMV (MCMV) to
examine if the contribution of the virus to immune
senescence is set by the (i) initial viral inoculum, (ii)
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inflation of T cell responses, (iii) or the balance between
functionally distinct effector CD4+ T cells. The work of
other groups studying the CMV response in humans is
discussed. Their work asks whether the ability to make
immune responses to new antigens is compromised by
(i) age and HCMV carriage, (ii) long-term exposure to
HCMV giving rise to an overall immunosuppressive
environment and increased levels of latent virus, or
(iii) adapted virus mutants (used as potential vaccines)
that have the capacity to elicit conventional and uncon-
ventional T cell responses.
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Introduction
CMV immune evasion during lytic infection
It is clear that primary human cytomegalovirus
(HCMV) infection elicits a series of robust cell-
mediated immune responses initially by innate NK cells,
followed by adaptive CD4+ and CD8+ Tcells and B cell
high avidity neutralizing antibodies (reviewed in
Jackson et al. 2011). These responses are essential in
controlling viral replication and dissemination as shown
by primary infection in either the immune-naive or
immunosuppressed. Here, uncontrolled virus replication
leads to end organ disease and morbidity and if left
uncontrolled, mortality (Carbone 2016; Chan and
Logan 2017; Kagan and Hamprecht 2017). Primary
HCMV infection has a profound effect on the human
immune system, leaving a permanent signature in the
form of phenotypically distinct T and NK cell subsets at
high frequencies (discussed in the accompanying article
by Souquette et al.). However, despite this robust host
immune response, HCMVis never cleared after primary
infection, but persists for the lifetime of the host. Crucial
to this lifelong persistence is the ability of the virus to
establish a latent infection, in which infected cells carry
viral genome but with limited viral gene expression and
the absence of production of new infectious virions
(Sinclair 2008). Importantly, the virus in these latently
infected cells has the capacity to sporadically reactivate,
leading to further rounds of antigenic stimulation and
secondary immune responses with the associated release
of inflammatory mediators. These rounds of virus reac-
tivation and immune system stimulation can potentially
drive further immune cell differentiation and increase
the frequency of CMV-specific T cells. The latter phe-
nomenon has been termed Bmemory inflation^ in the
murine CMV (MCMV) model and is characteristic of
CMV infection (O'Hara et al. 2012).
Paradoxically, HCMV is recognized as a paradigm
for a human pathogen encoding numerous viral immune
evasion proteins and microRNAs (miRNAs), which are
able to orchestrate a sophisticated array of immune
evasion mechanisms. The mechanisms that modulate
the infected cellular environment to limit immune rec-
ognition are most extensively expressed during lytic
infection, but it is starting to become clear that viral
gene activity during latency also acts to prevent immune
clearance.
During lytic infection, specific genes encoded by
HCMV can directly modulate innate/intrinsic immune
responses such as the interferon responses (Amsler et al.
2013) as well as both intrinsic and extrinsic apoptosis
pathways (Fliss and Brune 2012). The virus encodes
proteins that act as receptors for host inflammatory
cytokines, thereby reducing localized cytokine effec-
tiveness by acting as cytokine sinks (McSharry et al.
2012). HCMV encodes a number of viral homologs of
cytokines like UL146 (IL-8 like) and UL111a (vIL-10),
an immunosuppressive IL-10 homolog (Cheung et al.
2009; Stern and Slobedman 2008). IL-10 is a powerful
inhibitor of Th1 cytokines (such as IFN-γ and IL-2) and
also inhibits inflammatory cytokine production from
monocytes and macrophages which results in a decrease
in surface MHC class II expression and a reduction of
antigen presentation to CD4+ T cells (Opal and DePalo
2000).
HCMV interference with normal MHC class I ex-
pression to modulate CD8+ T cell recognition (see be-
low) would lead to reduced inhibitory signaling and NK
cell recognition of infected cells if additional viral mech-
anisms were not utilized. It is of little surprise then that a
substantial number of HCMV proteins target multiple
different pathways in order to modulate NK cell recog-
nition. These include preventing HCMV-infected cells
from expressing ligands at their cell surface that engage
activating NK cell receptors, such as MIC A/B and the
ULBP family which bind activating NKG2D; notably,
both MCMV (Lisnic et al. 2015) and rhesus CMV
(RhCMV) (Sturgill et al. 2016) also target NKG2D
ligands. The virus also promotes the expression of li-
gands that are able to engage inhibitory receptors. For
example, CMV encodes a viral MHC class I-like
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molecule, UL18, which binds the LIR-1 inhibitory NK
cell receptor (only expressed by a subset of NK cells)
and via a peptide processed from the viral UL40 protein
is able to promote cell surface expression of HLA-E
which binds the inhibitory heterodimer CD94/NKG2A.
HCMV also targets PVR and Nectin-2, important li-
gands of activating receptors DNAM-1 and Tactile
using UL141. UL141 of HCMV is further able to di-
rectly bind and inhibit expression of the TRAIL death
receptors (Nemcovicova et al. 2013; Smith et al. 2013),
a second avenue to dampen NK-mediated killing and a
mechanism also employed byMCMVvia m166 (Verma
et al. 2014), also reviewed in Lisnic et al. 2015 and
Wilkinson et al. 2008.
A number of HCMV-encoded genes expressed dur-
ing lytic infection can interfere with both MHC class I
and II restricted antigen processing and presentation.
Proteins encoded within the US2-11 gene cluster target
MHC class I and II molecules for retention within the
endoplasmic reticulum (ER), re-direct MHC for degra-
dation, and inhibit normal loading of peptides onto
MHC class I. It is again noteworthy that MCMV and
RhCMV have either viral homologs or other viral pro-
teins which target normal MHC class I processing and
antigen presentation (Lemmermann et al. 2012; Pande
et al. 2005). In addition, two structural tegument pro-
teins introduced into cells immediately upon infection,
UL82 (pp71) and UL83 (pp65), interfere with ER egress
of MHC I to the Golgi apparatus and with viral peptide
generation, respectively (reviewed by Noriega et al.
2012) . As discussed ear l ie r, whi le HCMV
downregulates classic HLA-A and HLA-B MHC I al-
leles, it has a mechanism that preserves HLA-E expres-
sion, and it is noteworthy that in RhCMV vaccine
vectors, peptide presentation via non-classical HLA-E
molecules is the basis for protective T cell responses,
and work discussed by Ann Hill later investigates to
what extent this is reflected in HCMV.
Immune evasion during latency
Virus-encoded miRNAs which are expressed during the
lytic viral cycle potentially provide an ideal mechanism
to mediate immune evasion in latently infected cells.
Recent evidence shows that many, if not all, of the
HCMV-encoded miRNAs are expressed during latency
(Lau et al. 2016); miRNAs have a major advantage in
that they are not antigenic as far as T cell recognition is
concerned. At least five miRNAs have been shown to
target components of the immune system during lytic
infection. miR-UL112.1 targets MICB, a ligand for NK
cell activating receptor NKG2D (Stern-Ginossar et al.
2007); miR-US4.1 downregulates ERAP-1, an amino-
peptidase which trims peptides for presentation by
MHC class I, leading to decreased HCMV-specific
CD8+ CTL recognition of HCMV-infected cells (Kim
et al. 2011); miR-UL148D targets the chemokine CCL5
(RANTES), which is a Tcell chemoattractant (Kim et al.
2012); miR-US25-2-3p targets inhibitors of TIMP3,
leading to increased MICA shedding (also decreasing
NK cell activation via NKG2D); and miRUl112-3p
targets the Toll receptor TLR2 (reviewed in Piedade
and Azevedo-Pereira 2016).
Three HCMV proteins, US28, UL111A, and UL144,
that are expressed in latently infected cells (Goodrum
2016) have known immune evasion functions during
lytic infection. US28 is a G protein-coupled receptor
that can bind many chemokines including CCL5,
MCP-1, MCP-3, MIP1-α, MIP1-β, and fractalkine.
Binding of these chemokines to US28 results in their
internalization and it has been suggested that US28
functions as a Bchemokine sink,^ reducing the local
concentration of these inflammatory and chemotactic
cytokines during lytic infection (Bodaghi et al. 1998).
A splice product of UL111A is expressed during latency
and encodes a viral IL-10 homolog (LAvIL-10) which
acts to downregulate MHC class II expression on ex-
perimental latently infected myeloid cells modulating
CD4+ T cell recognition (Cheung et al. 2009; Jenkins
et al. 2004; Jenkins et al. 2008). UL144 has sequence
similarity with members of the tumor necrosis factor
receptor superfamily (TNFRSF) (Benedict et al. 1999;
Locksley et al. 2001; Ware 2003) as well as the herpes
simplex virus entry mediator (HVEM). UL144 has two
putative immune evasion functions; the ecto-domain has
been shown to interact with B and T lymphocyte atten-
uator (BTLA)-inhibiting T cell proliferation in vitro
(Cheung et al. 2005) and the intracellular domain signals
via NF-κB, TRAF6, and TRIM23 to induce production
of the chemokine CCL22 which acts as a Th2 type
chemoattractant, possibly subverting the Th1 immune
response (Poole et al. 2008; Poole et al. 2009; Poole
et al. 2006).
Analysis of the secretome of cellular proteins pro-
duced by experimental latently infected CD34+ progen-
itor cells has identified a number of proteins, including
CCL8, cIL-10, and TGF-β, which are involved in im-
mune response regulation and chemotaxis (Mason et al.
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2012). CCL8 recruits CD4+ T cells to latently infected
cells, where the CD4+ T cell encounters the substantial
levels of the immune suppressive cytokines cIL-10 and
TGF-β produced by the infected cell. IL-10 and TGF-β
inhibit anti-viral IFN-γ and TNF-α cytokine secretion
and cytotoxic effector functions of HCMV-specific Th1
CD4+ T cells. In addition, uninfected bystander CD34+
cells were induced to secrete TGF-β and cIL-10 by the
latent CMV-infected cell secretome. This evidence
strongly suggests that the microenvironment around
latently infected CD34+ cells is immunosuppressive to
T cell function.
Viral proteins expressed during latency have impor-
tant roles in maintaining latency and preventing T cell
recognition. As such are they themselves targets for T
cells? LUNA, UL138, US28, and LAvIL-10 have been
shown to be recognized by T cells; however, the pre-
dominant response was mediated by CD4+ T cells,
many of which were not classic IFN-γ Th1 cells but
secrete the immunomodulatory cytokines cIL-10 and
TGF-β (Mason et al. 2013). In MCMV infection, IL-
10 producing CD4+ T cells have been isolated from
salivary glands, and in IL-10 KO mice or following
IL-10R blockage, the latent MCMV load is reduced.
This is consistent with the view that cytomegalovirus
uses regulatory T cells to prevent latently infected cells
from being recognized by the immune system
(Humphreys et al. 2007; Jones et al. 2010). Chris Ben-
edict describes later in this review the current evidence
for the immunomodulatory role of the IL-10 axis and its
impact on CD4+ T cell responses in MCMV infections.
Evidence for CMV manipulation of the immune system
with aging
As humans age, there are alterations to the immune
response that can be potentially detrimental to health.
For example, there is evidence from many studies that
people aged over 65 years are more susceptible to in-
fectious diseases (reviewed in Denkinger et al. 2015;
Kline and Bowdish 2016). However, in the healthy
elderly, overt disease caused by CMV is rarely seen
(Stowe et al. 2007), despite the dual manipulation of
the immune response by the virus and the effects of
natural aging. There is some limited evidence in humans
that modulation of the immune response by HCMV in
the aged is occurring, potentially resulting in less effec-
tive control of viral replication following reactivation of
virus. This hypothesis was suggested by the following
observations: (i) CMV DNAwas detectable in the urine
of old but not young donors (Stowe et al. 2007), (ii) an
increase in viral DNA has been detected in the blood of
older donors in a Japanese cohort (Furui et al. 2013), and
(iii) a UK study detected a significant increase in latent
CMV genomes (in peripheral blood CD14+ monocytes)
in people aged over 70 years (Parry et al. 2016). To
counteract this evidence, there have been studies of aged
CMV-positive people, which have been unable to detect
viral DNA in the blood (Stowe et al. 2007; Vescovini
et al. 2004). Wills and Jackson present in this review
some experimental evidence, which suggests there may
indeed be a slight loss of control of viral replication in
the aged compared to younger individuals.
There is however evidence that CMV infection might
be altering the balance of immune responses in aging,
from the strong association of CMV seropositivity with
increased mortality from cardiovascular disease
(Gkrania-Klotsas et al. 2012; Olson et al. 2013; Savva
et al. 2013; Simanek et al. 2011; Spyridopoulos et al.
2016). It has been proposed that the association of CMV
infection with cardiovascular disease may be a direct
result of pathology caused by the large expansion of
CD4+ CD28-negative T cell populations (Broadley
et al. 2017) commonly seen in CMV-infected individ-
uals (Weltevrede et al. 2016).
As previously discussed, HCMVinfection modulates
the hosts IL-10 pathway, both directly through expres-
sion of viral-encoded IL-10 homologs (Christiaansen
et al. 2015) and indirectly by altering the secretome of
the infected cell, in addition to generating cellular IL-10-
secreting CMV-specific CD4+ T cells. The production
of cellular IL-10 in response to HCMV antigenic stim-
ulation by CD4+ T cells has been observed in multiple
studies (Clement et al. 2016; Jackson et al. 2017a;
Mason et al. 2013; Schwele et al. 2012). Production of
IL-10 is a characteristic feature of regulatory T cells
(Tregs) (Zhu et al. 2010). CMV-specific Tregs in
humans have been identified in a number of studies
using various methods of Treg phenotyping (Clement
et al. 2016; Derhovanessian et al. 2015; Mason et al.
2013; Schwele et al. 2012; Terrazzini et al. 2014; Tovar-
Salazar et al. 2010). The Schwele et al. study demon-
strated that the generation of CMV-specific inducible
Tregs (iTregs) is most likely to be related to frequent
episodes of antigenic reactivation (Schwele et al. 2012),
a further method that the virus can use to modulate Tcell
populations. Suppressive CMV-specific iTregs have al-
so been identified in the expanded CD4+ CD28-CD27
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population (Tovar-Salazar et al. 2010) and their frequen-
cy increased with age and was associated with vascular
pathology along with expanded CMV-specific CD8+
effector T cell populations (Terrazzini et al. 2014). In
the murine model, it has been demonstrated that IL-10
secretion and Tregs reduce clearance of the virus and
increase persistence (Clement et al. 2016; Jost et al.
2014). This phenomenon has been demonstrated with
CD4+ T cells resident in the salivary glands
(Humphreys et al. 2007) and the liver (Popovic et al.
2017).
While clinical studies in humans have allowed for
important insights into pathologies associated with
HCMV persistence, by their very nature, they cannot
define if CMV is the cause of (i) pathology, (ii) a
consequence of underlying predispositions for associat-
ed pathologies, or (iii) merely an accidental and adven-
titious correlation. Defining cause-effect relationships in
HCMV immunology requires an experimental method
and such studies are hindered by the strict species spec-
ificity of this virus. Therefore, studies in animal exper-
imental models have relied on CMVortholog viruses in
their natural host species. While data from animal
models are not necessarily a direct representation of
natural events, this caveat holds for any dataset gener-
ated in a model, whether animal, experimental, or
mathematical.
Using the mouse model, it has been shown that CMV
infection results in memory inflation of T cell popula-
tions specific to particular MCMV protein epitopes
(Karrer et al. 2003) and is another example of the impact
CMVinfection can have on host immune responses over
a lifetime. Despite the dominance of a restricted clonal
MCMV-specific T cell populations as a proportion of
total T cell compartment (Karrer et al. 2003), it has been
clearly shown that the expanded memory T cells are still
functional and dynamic (Snyder et al. 2008). These cells
can be replenished to similar expanded levels following
depletion (Sims et al. 2015) and the inflation of this
population can occur, although less pronounced, in the
absence of reactivating or replicating virus (Snyder et al.
2011). The lessons that can be learnt from the manipu-
lation of the immune response by MCMV infection in
the mouse and its impact on aged T cell responses are
discussed later in this review by RamonArens and Anke
Redeker, and Luka Cicin-Sain.
Previously, it has been suggested that the expansion
of CMV-specific CD8+ and CD4+ T cells that have
been reported in some human aging studies is also
evidence of memory inflation within HCMV infection
(studies reviewed in Weltevrede et al. 2016). However,
unlike experiments in the murine model, most of the
evidence for memory inflation in humans comes from
cross-sectional age studies (Komatsu et al. 2003), rather
than longitudinal studies tracking the size of CMV-
specific CD8+ and CD4+ T cells within particular indi-
viduals over many years. It has been reported in indi-
viduals that as much as 10% of the total CD8+ T cell
compartment (Sylwester et al. 2005) and 5% of the total
CD4+ Tcell compartment (Pourgheysari et al. 2007) are
composed of CMV-specific responses. The expansion in
size of the CMV-specific T cell response in humans is at
the expense of T cell responses to other antigens. This
hypothesis has been used previously to explain the
observations from a number of studies where there is
an increase in all-cause mortality and susceptibility to
new infections in elderly CMV seropositive donors
(Hadrup et al. 2006; Olsson et al. 2001; Ouyang et al.
2004; Strindhall et al. 2013; Wikby et al. 2002). How-
ever, there have been a number of studies that dispute
this hypothesis. It has been shown that poor responses to
vaccines in older people are irrespective of CMV sero-
positivity (Furman et al. 2015) and the ability of older
people to respond to novel infections is not impaired by
an existing CMV infection (Lelic et al. 2012; Schulz
et al. 2015). Debbie van Baarle and Sara van den Berg
discuss the impact of CMV infection and consequential
immune modulation on the ability to respond to neo-
antigens in old age further later in this review.
Current research perspectives
The impact of aging on IL-10-secreting HCMV latent
antigen-specific T cells and latent viral load (Sarah
Jackson and Mark Wills)
Human cytomegalovirus (HCMV) infection and the
periodic re-activation of latent virus are generally well
controlled by Tcell responses in healthy people (Crough
and Khanna 2009; Jackson et al. 2011). Within older
donors, although overt disease caused by HCMV is
rarely seen (Stowe et al. 2007), there is some evidence
discussed in the introduction that suggests there may be
immunomodulation of the immune response in the el-
derly, potentially resulting in low-level viral replication
and dissemination without causing overt disease. Latent
CMV infection is characterized by limited viral
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transcription, with only a handful of viral genes (e.g.,
UL138, LUNA, US28, UL111A, and UL144) being
transcribed (Goodrum 2016). Previously, we have re-
ported that there are IFN-γ CD4+ T cell responses to
UL138 and LUNA proteins that are cytotoxic and there
are also cellular IL-10 responses by CD4+ T cells in
response to these latent associated proteins (Mason et al.
2013). Therefore, IL-10 is a candidate to mediate
immunomodulation of the CMV-specific immune re-
sponse during aging (Wills et al. 2015). To address the
question of whether long-term carriage of HCMV
changes the proportions of IL-10 and IFN-γ secreting
HCMV-specific T cell populations, Jackson and Wills
recruited a large cohort of CMV seropositive donors
aged 20–80 years in association with the Cambridge
Bioresource. We correlated the CD8+ and CD4+ T cell
responses with 11 HCMV proteins (5 latent ORFs and
pp65, pp71, gB, IE1, IE2, and US3) with age, HCMV
IgG levels, latent HCMV load in CD14+ monocytes,
lytic HCMV DNA copies in whole blood, and absolute
T cell population counts from whole blood.
The recruited donor cohort had a significant decline
in total and naïve CD8+ and CD4+ T cell numbers,
which has been reported previously in different aging
studies (summarized in Weltevrede et al. 2016). The
impact of CMV infection resulted in increased numbers
of differentiated CD8+ and CD4+ T cell populations,
which has often been described (Weltevrede et al. 2016);
however, this phenomenon was irrespective of donor
age in this cohort. Both CD4+ and CD8+ T cells
responded to stimulation with all 11 HCMV proteins,
and there was no accumulation of specific IFN-γ T cell
responses with increasing age; the CD4+ T cell IL-10
response was less frequently observed; however, over-
all, the breadth and magnitude of the IL-10 response to
HCMV proteins remains stable regardless of donor age.
IL-10-secreted CD4+ T cell responses were predomi-
nantly to latency-associated proteins (LUNA, UL138,
US28, and vIL-10), although the lytic-expressed pro-
teins pp71 and US3 also triggered a number of donors to
produce a CD4+ T cell-specific IL-10 response. Within
this cohort, CMV IgG levels remained stable and there
was no inversion in the CD4:CD8 ratio with increasing
donor age. Measurement of HCMV viral copy numbers
in CD14+ monocytes, a known cellular site of latent
CMV carriage (Reeves et al. 2005), did not reveal any
increase in viral levels in older donors, in contrast to a
previous UK study (Parry et al. 2016). Importantly,
however, we did see a significant correlation between
increased latent viral copies and the breadth and magni-
tude of the IFN-γCD8+ Tcell response. Our hypothesis
is that a larger latent HCMV reservoir may result in
more frequent HCMV re-activation and dissemination
events, which consequently lead to expansion of CMV-
specific T cell responses (and potentially re-seeding of
the latent pool). We did not detect HCMV DNA in the
blood of 104/105 HCMV seropositive donors included
in the study; interestingly, the one donor who did have
low levels of detectable HCMV DNA (274 copies/ml
whole blood) was an aged male donor who had an
inverted CD4:CD8 ratio and an above average number
of highly differentiated CD8+ T cells. This individual
result is supportive of the hypothesis discussed in the
introductory section, i.e., the elderly may not be as able
to control CMV replication as adequately as the young,
possibly due tomanipulation of the immune response by
the virus. This donor cohort was recruited on the basis of
HCMV serostatus and those suffering from immune-
altering illnesses or treatment for these conditions
(e.g., cancer, autoimmune disorders, and systemic ste-
roid treatment) were excluded from the study. This
stringent recruitment criterion may have resulted in less
healthy older donors, who may have lost control of
CMV replication to some extent resulting in low-level
viral dissemination, not being included in our study and
potentially skewing our observations (Jackson et al.
2017b).
It is also important to assess the functional capacity
of the CMV-specific T cells in response to the virus
directly; again, this approach may reveal defects in the
immune response to CMV in the elderly which are not
apparent in other population studies. In order to address
this problem, we have developed a viral dissemination
assay which we have used to interrogate the capacity of
HCMV-specific CD8+ (Jackson et al. 2014) and CD4+
T cells (Jackson et al. 2017a) to control the spread of
HCMV in vitro. We have demonstrated that purified
CD8+ and CD4+ T cell populations when isolated di-
rectly ex vivo are able to prevent the spread of the a
GFP-tagged clinical CMVisolate. To date, we have only
been able to use this methodology with a limited number
of donors aged over 65 years; however, in the CD8+ T
cell study, the evidence we do have suggests that the
older donors were capable of controlling viral spread,
but less efficiently compared to younger donors
(Jackson et al. 2014). This observation is also supported
by our CD4+ Tcell work, where the older donor includ-
ed in the study demonstrated a distinct loss of control of
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viral dissemination at low T cell to infected cell ratios,
which was not seen in the younger donors (Jackson et al.
2017b). These preliminary results suggest that the viral
dissemination assay will enable a more comprehensive
insight in to understanding if there is a diminution in the
effectiveness of CMV-specific T cells in the elderly in
the context of an active viral infection, where the full
armory of the virus immune evasion and manipulation
mechanisms are expressed.
Fibroblast-adapted HCMV vaccines elicit conventional
CD8+ T cell responses in contrast to RhCMV vaccines
(Ann Hill)
Studies using CMV as a vaccine vector in the monkey
model of AIDS have uncovered a highly unusual aspect
of CMV immunology. After serial passage in vitro,
HCMV isolates become adapted to the fibroblasts they
are grown in by losing the ability to form a functional
pentameric complex of glycoproteins that is needed for
entry into most non-fibroblast cells. When Louis Picker
and colleagues developed their rhesus (Rh) CMV vac-
cine vector, they used Peter Barry’s RhCMV BAC,
which was derived from a fibroblast-adapted RhCMV
(strain 68.1) and was pentameric complex-defective
(Hansen et al. 2009; Yue et al. 2016). RhCMVexpress-
ing proteins from simian immunodeficiency virus (SIV)
has provided impressive protection from a virulent SIV
challenge, and the strategy is being very actively pur-
sued to develop a vaccine for human AIDS (Hansen
et al. 2013a). Studies to elucidate the immunological
mechanism of the RhCMV-vectored vaccine’s efficacy
have yielded startling results: most of the antigen-
specific CD8+ T cells elicited by the vaccine are
completely unconventional, being restricted either by
MHC II or the rhesus equivalent of HLA-E (Hansen
et al. 2013b). Further studies showed that the unconven-
tional responses were only elicited by RhCMV lacking a
functional pentameric complex: restoring the
pentameric complex led to the generation of conven-
tional, i.e., classical MHC1-restricted, responses. These
unconventional responses are believed to be responsible
for the vaccine’s efficacy against SIV. If that is the case,
it is important to know whether the strategy could be
translated into a human vaccine.
CMV’s strict species specificity means that translat-
ing the monkey results to humans requires a shift in not
only SIV to HIV antigens but also of the vector, from
RhCMV to HCMV. Additionally, rhesus and human
immune systems have some differences. Most remark-
able is the rhesus MHC complex, which is extremely
polymorphic and polygenic. Up to 22 separate classical
MHC I isoforms are simultaneously expressed, contrast-
ing with up to 6 in humans or mice (de Groot et al.
2015). The MHCII loci are similarly polygenic and
polymorphic in monkeys. It could be that the unconven-
tional responses to RhCMV result from a distorted
CD8+ T cell repertoire that has arisen because of exces-
sive negative selection by this highly diverse MHC.
However, it should be noted that all other T cell re-
sponses studied in macaques have been conventional,
including those elicited by wild-type, i.e., pentameric
complex sufficient, RhCMV. Hence, it is likely that
immune system manipulation by CMV itself is respon-
sible for these responses, and that they would also be
seen in humans.
As a first attempt to look at this question, we studied
the CD8+ T cell responses to fibroblast-adapted HCMV
vaccines (Murray et al. 2017). Stuart Adler’s group had
conducted a dose escalation phase I clinical study of
four vaccines that are chimeras between Towne and
Toledo strains (Adler et al. 2016). All share the same
defect in the pentameric complex genes and have im-
paired cellular tropism in vitro for epithelial, endothelial,
and macrophage cells. We were able to study the CD8+
T cell responses in six subjects. All subjects responded
to HCMV IE1, and the typ ica l pa t t e rn of
immunodominant responses to one to two epitopes
was seen. This contrasts with the responses reported in
monkeys, which responded to an average of 36 epitopes
in RhCMV IE1. Most responses in the human subjects
were mapped to a minimal epitope, and HLA restriction
was mapped for eight epitopes. Each epitope that could
be mapped was conventionally MHC I restricted, and
two subjects responded to previously identified HCMV
epitopes. Antibody blockade and use of HLA-E
transfectants provided no evidence to suggest that the
remaining responses were unconventional.
The response to these pentameric complex-deficient
HCMV vaccines thus appears to be predominantly or
completely conventional in human subjects. This could
be a result of differences in human and monkey immune
systems. However, it should be noted that although both
are pentameric complex deficient, the Towne-Toledo
chimeras and RhCMV 68-1 differ in the genetic muta-
tions that result in the functional deficiency. It will be
important to understand the viral mechanism for
eliciting the unconventional responses to have the best
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chance of eliciting the same responses in humans,
should they prove to be important for the vaccine’s
efficacy.
The effect of CMVon the response to influenza virus
vaccination (Debbie van Baarle and Sara van den Berg)
Immunosenescence is the age-related deterioration of
immunocompetence which is reflected in a poorer re-
sponse to (new) antigens and leads to increased suscep-
tibility of elderly to infection and lower response to
vaccination. HCMV infection has been shown to en-
hance deleterious age-associated changes in immunity
and may thereby contribute to poor responses to vacci-
nations. Indeed, it has been shown that HCMV is part of
the immune risk profile (IRP), which is associated with
all cause of death (Olsson et al. 2001). Based on a
systematic review of studies performed between 2004
and 2014 on the role of HCMV persistence on T cell
immunosenescence in people aged 50 and older, we
observed that CMV mainly seems to enhance
immunosenescence through increasing the levels of the
highly differentiated effector memory (TEM) and
CD45RA-expressing effector memory (TEMRA) cells
in the CD8+ and CD4+ T cell pools (Weltevrede et al.
2016), although an elegant study (Wertheimer et al.
2014) suggested also a decline in CD4+ T cells in
HCMV-positive individuals. Furthermore, CMV infec-
tionwas also shown to be associated with intrinsic B cell
defects (Frasca et al. 2015). How these changes may
affect responses to other infections or vaccinations and
whether these shifts within the T cell compartments in
HCMV-seropositive elderly are related to susceptibility
to infectious diseases remain to be fully investigated.
In humans, in whom the effect of HCMV has espe-
cially been studied in the context of influenza virus
vaccination which is shown to lead to less protection
in older individuals, the data is less clear (see box/Fig.
1). Four studies suggest a negative effect of HCMV to
antibody responses to flu vaccination on elderly (Alonso
Arias et al. 2013; Derhovanessian et al. 2014; Frasca
et al. 2015; Trzonkowski et al. 2003). This negative
effect of HCMV was also found to be present in young
individuals in two additional publications (Turner et al.
2014; Wald et al. 2013). However, two studies observed
no effect of HCMVon influenza antibody responses in
elderly (den Elzen et al. 2011; Haq et al. 2016), one of
which observed a positive correlation between IgG
HCMV levels and the influenza antibody titer,
suggesting a beneficial effect of HCMV. Moreover, a
recent paper by Furman et al. observed an enhancing
effect of HCMVon the antibody response to influenza in
young, but not in old individuals (Furman et al. 2015).
These discrepancies in the literature may result from
differences in pre-existing immunity to the seasonal
influenza vaccination in participants. We hypothesize,
therefore, as shown in HCMV models in mice (Cicin-
Sain et al. 2012; Mekker et al. 2012) that CMV infection
will have a larger impact on/impair the antibody re-
sponse to neo-antigen influenza vaccinations.
In our study, focusing on middle-aged individuals
(n = 287), of whom 60% were HCMV-seropositive
and who were vaccinated with the novel pandemic
influenza A strain (pH1N1) vaccine during the 2009
influenza pandemic, we found no effect of HCMV
infection on antibody response to influenza vaccination,
despite the fact that we do observe an age-related effect
on influenza antibody responses in this group (S. P. H.
van den Berg, manuscript in preparation). As detectable
titers to the novel pandemic influenza strain were pres-
ent before vaccination in 23% of the individuals, this
still may have contributed to the lack of effect of CMV
on influenza antibody responses. However, correction
for pre-titers and other potential confounding factors
like age, sex, and previous vaccination did not change
the observed result. Furthermore, our data may even
suggest a beneficial/positive effect of CMV infection
on the protection rate after influenza vaccination in these
adults. These data add to the discussion on the role of
CMV infection on vaccination responses and suggest a
scenario in which CMV infection may be beneficial
during the first decades of life, but this effect may be
lost upon aging.
In mouse models of MCMV infection in which
MCMV-infected mice are challengedwith neo-antigens,
data are clear and specific defects in immunity to newly
incoming pathogens have been reported leading to low-
er protection against these new infections (see Ramon
Arens and Anke Redeker below). In these studies
MCMV was shown to have effect mainly on the T cell
compartment but effects on the antibody response were
also observed. Prior MCMV infection was shown to
result in significantly reduced (Cicin-Sain et al. 2012)
or remodeled (Smithey et al. 2012) CD8+ T cell re-
sponses to challenging infections and elevated viral
loads (Mekker et al. 2012). As HCMV mainly impacts
the T cell repertoire and the T cell response plays a
bigger role in cross-reactive immunity towards different
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influenza strains as well as vaccine-induced protection
in later life, the question is whether we can find evidence
for decreased cellular immune responses and whether
previous HCMV infection would affect immune protec-
tion after vaccination in humans of different ages. A
recent study shed first light on this by showing that
CMV seropositivity was associated with a decline in
Granzyme B responses to influenza and may predict
increased susceptibility to influenza in older adults
(Haq et al. 2016). In contrast, Theeten et al. show a
positive relation between cellular IFN-γ and Granzyme
B responses to CMV-pp65 antigen and influenza N1
antigen (Theeten et al. 2016). Thus, with regard to the
effect of CMVon cellular immune responses to influen-
za in humans, the jury is still out.
Impact of the infectious dose of CMVon the severity
of immune senescence (Ramon Arens and Anke
Redeker)
The controversies with respect to the role of CMV in
immunosenescence including the impact of CMV infec-
tion on vaccines and encountering other pathogens as
discussed by van Baarle and van den Berg above might
relate to the differences in the immunological response
rate to HCMV, which varies significantly. In the human
population, the percentages of CMV-specific T cells
occupying the memory T cell compartment are highly
variable (ranges from 0.01 to 50%) (Vescovini et al.
2014). The average HCMV-specific memory T cell re-
sponse is ~10% of the total memory T cell compartment
and is compared to other infections, extraordinarily high
(Sylwester et al. 2005). In old age, it has been estimated
that the HCMV-specific memory T cell pool can occupy
up to 50% of the total memory compartment (Vescovini
et al. 2007). The high variation in the T cell response to
CMV is likely related to the significant difference in the
quantity of CMV found in bodily fluids such as breast
milk, saliva, and urine (101–105 copies/μl), causing
horizontal transmission of CMV (Cope et al. 1997;
Kouri et al. 2010).
The mouse studies that have been performed previ-
ously, wherein the impact of long-term CMV infection
on host immunity was investigated (Cicin-Sain et al.
2012; Mekker et al. 2012; Smithey et al. 2012), showed
a relationship between CMV positivity and immune
senescence. Specifically, these studies demonstrated that
long-term latent CMV infection induces high numbers
of effector-type like memory CD8+ T cells reactive to
CMV, while newly generated CD8+ T cell responses to
heterologous viral infections were diminished. Howev-
er, this was not followed by an increase in mortality
from heterologous viral infection (Marandu et al. 2015).
This is in contrast with the controversial data observed
in humans. However, these mouse studies used relative-
ly high doses of virus for infection leading to high
CMV-specific T cell responses. Hence, the diversity in
the HCMV-specific immune response as seen in humans
was not taken into account. Previously, we have shown
that the degree of accumulation and phenotype of infla-
tionary CMV-specific CD8+ T cells corresponds to the
size of the initial infectious dose (Redeker et al. 2014).
To gain insight into the controversial results with respect
to the possible contribution of CMV to immune senes-
cence in humans, and whether this is related to the large
variance in the frequency, phenotype, and accumulation
of CMV-specific memory T cells, we performed a high-
ly controlled prospective study. We infected mice with
Fig. 1 Overview of studies
performed and their findings on
the role of CMV infection on the
immune/antibody response to in-
fluenza vaccination. Overview of
Alonso Arias et al. 2013, den
Elzen et al. 2011, Derhovanessian
et al. 2013, Frasca et al. 2015,
Furman et al. 2015, Strindhall
et al. 2016, Trzonkowski et al.
2003, Turner et al. 2014, and
Wald et al. 2013
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different inoculum dosages of MCMVand investigated
longitudinally the influence of lifelong CMV infection
on alterations within the peripheral T cell pool. Our
results show that the initial viral inoculum determines
the degree of CMV-induced immune alterations in life-
long infection. A heightened MCMV infection resulted
in reduced frequencies of naive circulating CD8+ Tcells
(CD44lowCD62L+KLRG1−) and, on the other hand,
increased the accumulation of effector memory (EM;
CD44highCD62L−KLRG1+) CD8+ T cells. A remark-
able correlation becomes apparent between the magni-
tude of the CMV-specific CD8+ T cell response and the
EM phenotype of these cells. Basically, the higher the
magnitude of response, the higher the frequency of the
EM-like CD8+ T cells. Importantly, these correlations
between the CMV-specific CD8+ T cell response and
memory phenotype were also apparent in CMV-infected
humans.
To specifically assess the role of the CMV inoculum
size on the development of heterologous anti-viral im-
munity, aged MCMV-infected mice received a chal-
lenge with lymphocytic choriomeningitis virus
(LCMV). Strikingly, mainly in the mice that were in-
fected with the highest dose of MCMV, the LCMV-
specific CD8+ T cell expansion was impaired. The latter
correlated with a reduced activation status of the
LCMV-specific CD8+ T cells, and importantly, the con-
trol of LCMV infection was hampered. This detrimental
effect of high-dose infection was not observed in young
mice, where even a positive effect was apparent. Thus,
only in the high-dose-infected agedmouse the control of
heterologous infection was found to be impaired. This
suggests that predominantly in aged individuals with
pronounced HCMV-induced perturbations, detrimental
effects for these persons can be contributed to CMV
while in persons with low HCMV-specific responses,
negligible effects of CMVare present. Instead, in young
persons, HCMV may even have beneficial effects. To
settle these statements, additional prospective longitudi-
nal studies are necessary that incorporate stratification
based on the quantity and quality of the HCMV re-
sponse in each individual.
CD4 T cell control of CMV persistence during initial
infection: how does it impact viral shaping
of the immune system over a lifetime? (Chris Benedict)
As discussed above, HCMV-specific CD4+ T cells can
secrete a variety of cytokines, producing some more
frequently when they encounter their cognate antigens
expressed by latently infected cells (e.g., IL-10). How-
ever, it is very challenging to assemble cohorts to assess
T cell effector and memory responses during primary
HCMV infection, given it is largely asymptomatic in
healthy people. Therefore, most studies have measured
the function and phenotype of these cells in persons
already infected for many years/decades, long after the
acute and high-level persistent replication phases of
infection have been controlled. As the mouse provides
a tractable model to study all three phases of CMV
infection (acute, persistence, and latency), and T cells
induced by MCMV show similar phenotypes and func-
tions to that of HCMV, we set out several years ago to
identify the first MCMVepitope-specific CD4+ T cells,
characterizing 15 in C57BL/6 (B6) mice (I-Ab
restricted) (Arens et al. 2008) and two in BALB/c (I-
Ad restricted) (Verma et al. 2015). Our recent construc-
tion of several MHC II tetramers has allowed the en-
richment and characterization of these cells from lym-
phoid and non-lymphoid tissues, a necessity given they
are present at markedly lower numbers than their CD8+
T cell counterparts (Moon et al. 2007).
There is no identifiable IL-10 sequence ortholog
encoded by MCMV, unlike the primate CMVs; howev-
er, various host immune cell types produce IL-10 during
both the acute and persistent phases of infection. CD4+
T cells secrete the majority of this IL-10 during MCMV
persistence in the salivary glands of B6 mice (Clement
et al. 2016), where high-level viral replication continues
for several months. Studies performed a decade ago
showed that signaling by the IL-10 receptor sustains
MCMV replication at this mucosal site (Humphreys
et al. 2007) and restricts the expansion of CD8+ and
CD4+ T effector cells (Jones et al. 2010), with a similar
role also reported for RhCMV vIL-10 in monkeys
(Chang and Barry 2010). In turn, IFN-γ+ CD4+ Th1-
like cells play a key role in the eventual resolution of
MCMV persistence (Lucin et al. 1992; Walton et al.
2011), while their production of TNF appears unneces-
sary for this (Fleck et al. 1998; Walton et al. 2011).
Consequently, the relative numbers of CD4+ T effector
and memory cells that produce IFN-γ and IL-10 during
the various phases of CMV infection likely form an axis
that regulates the magnitude, duration, and reactivation
of CMV in both mice and men.
It has been shown that the ability to mounting a
robust, IFN-γ+ secreting HCMV-specific CD4+ T cell
response correlates with reduced duration of persistent
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CMV replication in the kidneys of young children (Tu
et al. 2004). Initial MCMV infection induces a strong
IFN-γ + CD4+ T cell response, and these cells are
present in the salivary gland within 1 week. However,
they are not sufficient to resolve viral replication at this
time of Bearly persistence,^ due at least in part to the
high levels of IL-10 that are commensurately produced.
Intriguingly, our past studies identifying MCMV
epitope-specific CD4+ T cells found that some re-
sponses did not expand until much later times following
infection, after systemic replication was controlled and
persistence had been established. It is interesting to
postulate that these Blate-rising^ CD4+ T cells might
display distinct anti-viral effector functions during viral
persistence compared to their conventional counterparts,
as they would likely differentiate in a unique inflamma-
tory environment. In turn, it is possible that the duration
of CMV persistence prior to latency establishment may
influence the viral impact on immune aging. For exam-
ple, a longer persistent replication phase may result in a
higher initial Bset point^ of CMV-specific cellular re-
sponses and latent virus load, with these differences
being amplified over a subsequent lifetime. Perhaps,
this contributes to the dose-dependent impact of initial
MCMV infection on the T cell compartment in old mice
described by Arens and Redeker. Finally, how these two
distinct populations of conventional and late-rising
CD4+ T cells induced by MCMV might equate to the
HCMV-specific CD4+ T memory cells seen by Wills
and colleagues that preferentially recognize viral anti-
gens expressed during the lytic and latent phase of
infection is unclear, if they do at all, but it is an intrigu-
ing question.
Immune evasion of memory inflation in the murine
model (Luka Čičin-Šain)
The mouse model (MCMV) reflects the balance be-
tween the latent virus and the host immune system,
where a hierarchical and redundant cellular immune
response keeps CMV from reactivating (Polic et al.
1998). The continuous low-level transcription of viral
genes (Kurz et al. 1999) results in the persistence of T
cell infiltrates in the lungs of latently infected mice
(Podlech et al. 2000), where immunodominant effector
or effector memory T cells against epitopes transcribed
in latency prevail (Holtappels et al. 2000). The expan-
sion and persistence of T cells against immunodominant
CMV antigens has been aptly named memory inflation
(Karrer et al. 2003) and it was shown that it reflects T
cell responses to HCMV (Komatsu et al. 2003). Impor-
tantly, memory inflation is an expansion of effector T
cells against defined MCMV-specific epitopes, but the
size of the effector T cell pool remains unaltered (Cicin-
Sain et al. 2012), implying that memory inflation is a
f o cu s o f CD8+ T ce l l r e s pon s e s on f ew
immunodominant epitopes at the expense of subdomi-
nant ones, rather than a general expansion of T cell
responses to cytomegalovirus. The size of the inflation-
ary response depends on the latent transcriptional activ-
i ty of the viral genes encoding the epitope
(Dekhtiarenko et al. 2013) and on its availability for
process ing by the cons t i tu t ive proteasome
(Dekhtiarenko et al. 2016; Hutchinson et al. 2011),
implying that CD8+ T cell re-stimulation may occur
by antigens presented directly on latently infected cells.
In fact, the expansion of MCMV-specific CD8+ T cells
in memory inflation requires antigen presentation on
non-hematopoietic cells (Seckert et al. 2011; Torti
et al. 2011), likely from within the latently infected cell.
It has remained somewhat controversial if this phenom-
enon depends on the viral evasion of the immune sys-
tem, or if it occurred independently of it.
Akin to the HCMV situation, MCMV devotes a
substantial part of its genome to the evasion of the
immune system. It has developed multiple strategies to
downregulate MHC I molecules from the surface of
infected cells and thus avoid detection by CD8+ T cells
(Wagner et al. 2002). However, an MCMV mutant
lacking all viral genes known to interfere with MHC I
surface presentation induced similar hierarchies of
CD8+ T cell immunodominance as the wild-type
MCMV, both in primary and in latent infection
(Munks et al. 2007). This observation might be antici-
pated if one considers that the known MHC I
downregulators m04, m06, and m152 are lytic viral
genes that are unlikely to be expressed during virus
latency. Surprisingly, another study showed that the
MCMV lacking these three genes induces a weaker
CD8+ T cell response (Bohm et al. 2008), arguing for
a paradoxically improved priming and inflation state in
the presence of immune evasion. The latter study
showed that immune evasive genes protect the virus
from the antiviral activity of CD8+ T cells, allowing it
to proliferate longer and to higher titers in draining
lymph nodes during primary infection (Bohm et al.
2008). Therefore, it was proposed that immune evasion
enhances viral replication, antigen availability for
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priming, and consequently, the size of the inflationary
response. The conditions of primary infection and inoc-
ulum define the size of the latent reservoir (Reddehase
et al. 1994) and of the inflationary response (Redeker
et al. 2014). In particular, the latent MCMV burden in
the spleen, but not in in the lungs, is associated with a
more pronounced inflationary response to MCMV
(Oduro et al. 2016). Consequently, by improving viral
fitness in the primary infection and by increasing the
number of cells carrying latent viral genomes, immune
evasive genes may indirectly affect the size of the infla-
tionary response, although they are not expressed at the
time of latency and T cell expansion.
This does not exclude possible additional effects
of viral genes at the time of latency. The CMV
genome is the largest known among mammalian vi-
ruses and the function of numerous viral genes re-
mains unknown (Rawlinson et al. 1996). Beyond the
viral genes that downregulate MHC I from cell sur-
face, CMV expresses numerous additional genes
which may interfere with CD8+ T cell priming, for
instance those interfering with costimulatory signal 2
or 3 (Doring et al. 2014; Loewendorf et al. 2004).
Therefore, it is likely that numerous additional genes
interfere with the immune response and it cannot be
excluded that their activity may influence the size
and the quality of the inflationary T cell response. A
shotgun approach to the study of immune evasion by
targeted deletion of large genomic regions rich in
immune evasive genes yielded an MCMV variant
lacking 34 viral genes in regions rich in immune
evasive genes (Cicin-Sain et al. 2007). While this
mutant induced inflationary responses that could not
be distinguished from wild-type MCMV in size
(Cicin-Sain et al. 2007), it cannot be excluded that
other viral genes—including the essential ones—may
affect the T cell responses. Therefore, future studies
in models of in vivo infection may inform us if
immune evasion acts actively during viral latency
and if it defines the size and the functionality of the
responding T cell pool.
Future perspectives
The preceding summaries of current research work in
both humans and mouse models go some way to
assessing the impact that CMV infection and viral im-
mune evasion may have on the immune response to
CMV and the immune response more generally. How-
ever, there are still many unanswered questions, and the
real impact of CMV manipulation of the immune re-
sponse on the elderly remains to be fully ascertained.We
propose that future studies may wish to consider the
following issues:
& To what extent is the association of CMV infec-
tion with detrimental changes to the immune re-
sponse in aging a co-incidence or a real phenom-
enon, and, if so, is the virus the direct causative
agent or are the changes to the immune response a
bystander effect of CMV infection? While this
question is not straightforward to address in
humans, due to the many unknowns in the CMV
infection history of an individual subject, design-
ing clearly defined population studies which mea-
sure multiple parameters (e.g., pertinent medical
history, socio-economic background, country or
region of birth, absolute immune cell counts,
CMV-specific immune responses and quality/
quantity of these—both T cell and immunoglob-
ulins, CMV DNA quantification) will help going
forward. Additionally, the adoption of similar
strategies and measurements in geographically
distinct donor cohorts will enable comprehensive
intra-study comparison, thus increasing the over-
all power of the conclusions that can be derived.
& Is CMVinfection an important comorbidity factor in
human aging? To address this question will require
comparison of the impact of CMV infection in less
healthy elderly donor cohorts, e.g., does CMV in-
fection in donors with cardiovascular-related health
problems lead to less control viral reactivation and
dissemination, compared to age-matched healthy
people. This question could be asked in a number
of different disease cohorts; however, in cases of
cancer or auto-immune diseases (e.g., rheumatoid
arthritis), the impact of these conditions on the im-
mune response will have to be accounted for when
interpreting the results.
& Does CMV-mediated modulation of the immune
response in the elderly result in low-level viral
reactivation and dissemination, that is below the
level required to present as overt clinical disease
but nevertheless may drive inflammatory pathol-
ogies? This will require that future studies incor-
porate a virological assessment of donors, with
quantification of virions present (or not) in blood,
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saliva, and urine alongside measuring typical im-
munological parameters, could be highly
informative.
& As illustrated in this review, the use of the mouse
model has been very important in understanding
the multiple consequences of CMV infection, im-
mune evasion, and manipulation on the host im-
mune response. However, this does not replace
the need for studies to be performed in humans,
particularly in the context of immune aging re-
search. Extrapolating results from murine aging
studies to humans requires consideration of a
number of key differences: (i) the contribution
from thymic output replenishing the peripheral
T cell compartment is higher in mice than men
(Appay and Sauce 2014); (ii) mouse telomeres
are proportionally longer than humans; therefore,
it is less likely that immune cells from aged mice
will exhibit a telomere-mediated replicative se-
nescence phenotype compared to humans
(Akbar et al. 2001), and (iii) are genetically sim-
ilar mouse breeds sterile housed for 600 days or
more equivalent to human subjects with wide
genetic variability and decades of exposure to
multiple antigens from many different environ-
ments. These important differences between mice
and man have led to the use of longer lived
animal models, including baboons (Willis et al.
2014) and the rhesus macaque model (Cicin-Sain
et al. 2011; Oxford et al. 2015), to interrogate the
interaction of CMV and aging. Again, there can
be issues with cross-species comparisons; as
discussed in this paper by Ann Hill, the T cell
responses generated to vaccines for RhCMV and
HCMV in the respective hosts show distinct dif-
ferences in the breadth and type of CD8 + T cell
responses produced.
& In order to determine if the effect of CMV infec-
tion on global immune responses in aging is truly
detrimental and requiring of medical intervention
in older people will require far stronger evidence
in order to convince the wider medical communi-
ty of its need. For many physicians, CMV infec-
tion is not perceived as a major problem, because
unless the patient is immune compromised or
immune naïve, CMV-mediated disease is not
commonly observed. Therefore, to provide a truly
convincing argument in the future will require
studies which also consider whether aging or
putative lifelong CMV infection alters the quality
of the immune response to the virus and then
considers whether there are consequences for
overall health. Many of the historical population
studies performed to interrogate whether CMV is
detrimental in aging in humans have relied on
comparing total immune cell phenotypes with
CMV serology relied on as a measure of deter-
mining infection history. Reliance on CMV IgG/
IgM serology to identify CMV infectious history
may be problematic, as anecdotal evidence has
shown that there are discrepancies in the results
seen from CMV serology test kits from different
manufacturers, and CMV-specific T cells have
been detected in CMV seronegative donors.
& Lastly, it is clear from murine studies that not only
does CMV infection persist in different tissues but
also the CMV-specific T cell response that is resi-
dent in these tissues can have distinct phenotype and
functions (Verma et al. 2015). Within humans, the
peripheral blood provides a mere snapshot of the
immune response, comprising only 2% of the bod-
ies’ total lymphocyte numbers (Blum and Pabst
2007). A recent study has identified CMV-specific
CD8+ T cells in many different tissue sites in
humans (via a collaboration with an organ transplan-
tation body), and the results further suggest that
CMV-specific T cells isolated from different tissues
can also have distinct phenotype and functionality
(Gordon et al. 2017). While it is not possible to
access multiple tissue sites at one time in living
human donors, there are possibilities through surgi-
cal collaborations to access immune cells from dis-
parate tissue sites enabling comparison with im-
mune cells isolated from peripheral blood. Studies
have been published investigating the presence of
CMV infection or CMV immune responses in the
mucosal tissue (Clement et al. 2016), the lung via
bronchoalveolar lavage fluid (Poole et al. 2015), and
the bone marrow (Palendira et al. 2008). Interrogat-
ing the function and quality of tissue resident CMV-
specific immune cells may help to inform our un-
derstanding of the frequency of CMV reactivation
and dissemination and whether this is detrimental to
an individual’s health.
Overall, it is clear there are still many questions
regarding the impact of CMV-mediated immune eva-
sion and manipulation of the immune system with aging
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that remain incompletely answered and that require
further research.
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